Medical Products Executive joins TruScreen Board

NZX and Media Release 20 August 2018 NZX Limited WELLINGTON Experienced Medical Products Executive joins TruScreen Board Cervical cancer technology company, TruScreen Ltd (NZAX, TRU), is pleased to announce the appointment of Mr. Con Hickey as an independent director on the TruScreen board. Mr Hickey has more than 30 years experience in the Medical Device industry, including holding senior executive roles for multinational companies such as Welch Allyn, a leading global manufacturer in frontline diagnostic and screening equipment. Currently the Managing Partner of CONX Partners, Con's particular skillset includes strategic planning, channel management, talent development and business and market development. His geographic expertise has been focused on the high growth countries of the Asian Pacific region, including China and India, with extensive global industry connections. Chairman of TruScreen, Mr Robert Hunter, commented: "Mr Hickey brings a wealth of relevant experience to TruScreen. He has a great commercial and sales background, which is ideal for us as we move from a product improvement phase to full scale commercialisation of our unique cancer screening technology." Mr Hickey is ordinarily a resident of New Zealand and has been appointed by the current TruScreen directors, as permitted under TruScreen's constitution. He will hold office until TruScreen's 2018 Annual Meeting at which time he will offer himself for re-election by shareholders. ENDS For more information visit www.TruScreen.com or contact: Martin Dillon TruScreen Chief Executive Officer Email: martindillon@TruScreen.com Media Liaison Jackie Ellis Email: jackie@ellisandco.co.nz Phone: +64 27 246 2505 About TruScreen: TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection. End CA:00322403 For:TRU Type:ADMIN Time:2018-08-20 08:30:42